The session room of the Royal Academy of San Dionisio, of Sciences, Arts and Letters will be the stage in the coming weeks of the Medicine and Society cycle coordinated by Juan Carlos Durán Alonso, Academic Number of this corporation.
The series, made up of three conferences, starts on the afternoon of Tuesday, November 15 with the presence of José Javier Pérez Venegashead of the Rheumatology Service of the Virgen Macarena University Hospital in Seville, director of the Andalusian Plan for rheumatic diseases. ‘Challenge in the management of rheumatic diseases’ is the title of the first of the dissertations and will begin at 7:30 p.m., free access until completing the capacity of the session room of the academic headquarters, located at Calle Consistorio, 13.
A week later the second of the conferences of the cycle will take place. On this occasion, Tuesday November 22 Alipio Mangas Rojasprofessor at the Faculty of Medicine, director of the department ofMedicine of the University of Cádiz, will focus on the ‘Cholesterol, clinical relevance and importance of treatment’.
Finally, the November 29th it will end with the conference ‘Fifty years of the history of Cardiovascular Surgery’which will deliver Carlos Infantes Alconcardiovascular surgeon, Faculty of Medicine of Seville and president of the Royal Academy of Medicine and Surgery of Seville.
The first two dissertations will be presented by Juan Carlos Durán Alonsoacademic of Number and coordinator of the cycle, while in the last of the sessions Juan Salido Freyre will make a presentation, President of the Royal Academy of San Dionisio.
At the opening of the cycle, José Javier Pérez Venegas intends to analyze rheumatic diseases (RD)a term that encompasses more than 200 very diverse and complex entities, with predominantly immunogenic, inflammatory and degenerative etiopathogenic mechanisms and that manifest clinically in the musculoskeletal system and in other organs at the systemic level.
When talking about musculoskeletal diseases (MS), those processes that affect well-defined anatomical structures (bones, muscles, joints and periarticular structures) are described. and thatThey include inflammatory joint processes, axial pain, local or regional pain, bone diseases, soft tissue rheumatism and systemic connective tissue diseases. However, the term of EM does not measure well the possibility of systemic involvement of vital organs.
To facilitate knowledge and estimate the dimension of these diseases, the National Strategy for Rheumatic and Musculoskeletal Diseases includes both definitions under the term Rheumatic and Musculoskeletal Diseases (RMD), which would include, among others, all joint diseases, those of the connective tissue, processes that affect the spine, soft tissue rheumatism, osteoarthritis and osteoporosis.
The most notable features of ERyME are their high prevalence in the general population, their frequent tendency to become chronic, and their potential to cause disability. They are generally associated with pain and limitation of mobility with particularities in their clinical manifestations, morbidity and mortality. They have a great impact on the quality of life and functionality of people who suffer from them and are an important cause of consumption of health resources and loss of work productivity. In Andalusia, they cause the greatest burden of disease (27%), followed by diseases of the circulatory system and cancer. The frequency of these diseases varies according to sex and age groups, depending on the pathology. However, women present this type of the same more frequently, compared to men, regardless of their age, social class, cultural level or employment situation.
The prevention of some groups of MSRD is closely associated with the identification, prevention, elimination, and control of occupational risks, and with the promotion of healthy lifestyles, such as maintaining an adequate diet and engaging in activityphysical.
ERyME are the second most frequent cause of medical consultation in the European Union (EU), where 1 in 5 people receive chronic treatment for a rheumatic disease, and in most countriesconstitutes between 10 and 20% of consultations in Primary Care (PC). Approximately 23% of the Spanish population over 20 years of age report being diagnosed with some ERyME.
One reality to bear in mind is that close to 60% of workers in the EU, both men and women, state that they have suffered from work-related musculoskeletal disorders in the last few years.twelve monthsand the 2009 Fit for work in Europe report concluded that one in six European workers (44 million in total) suffered from a chronic musculoskeletal problem that affected to their ability to work.
In total, more than 100 million European citizens suffer from chronic pain of musculoskeletal origin, and this type of disorder gives rise to the highest recorded proportion of temporary incapacity (TI) onany other type of ailment.
Taking into account the high prevalence of these diseases and their relationship with a lower quality of life and the deterioration of the functional capacity of patients, as well as the social, family or work impact and the progressive aging of the population, it seems necessary to make a effort in the appropriate care planning of the same, based on the needs of the patients, which encompasses education, prevention, early diagnosis and the definition of predetermined treatment objectives that allow satisfactory health results for the patient.
In the last fifteen years, different strategies have been developed at European, national and regional level that aim to respond to the care needs of ERyME.
In our Community, the Andalusian Plan for Rheumatic and Musculoskeletal Diseases (PAERME) was published in 2018, where the strategic lines are drawn to respond to the needs ofcitizens and whose fundamental axis is communication and collaboration between healthcare levels (Primary Care/Hospital Care) and between professionals in the hospital field. Is communication would make it possible to standardize care and reduce variability in clinical practice, as well as to develop new strategies that increase the quality, effectiveness and safety of health care, with the participation and decision-making capacity of the citizen. Likewise, the promotion of projects that incorporate health promotion and disease prevention as tools to improve the quality of life of patients is promoted.
In this way, we will be able to guarantee the resolution of the great challenges in the management of RDMS, such as prevention and early diagnosis, the introduction of efficient treatment strategies based onevidence and obtaining adequate health results. The objective will be to allow the normal development of people in the individual, family, social or work environment.
But, in addition, we will be able to value the new immunogenetic and pharmacogenomic techniques that favor individualized treatment of patients. This is the way to carepatients with rheumatic diseases in a public health of excellence.